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Sorafenib (Nexavar; Bayer, Leverkusen, Germany)
is a multikinase inhibitor that shows efficacy in a
variety of tumours and has been recently approved
for the treatment of multifocal and surgically unre-
sectable hepatocellular carcinoma (HCC). Sorafenib
blocks the growth of tumour cells by inhibition of
several pathways that both interfere with angiogen-
esis and induce apoptosis of HCC cells. Both in HCC
cell lines and in murine models, sorafenib has been
shown to antagonize the angiogenic effect of vascular
endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) on their receptors
VEGFR2 and PDGFR respectively. Furthermore,
sorafenib has a direct effect on cell proliferation
with mechanisms that are partly unknown but that
involve the RAF/MEK/ERK signalling pathway,
which plays a key role in the development of many
tumours including HCC [1]. Antiangiogenic drugs
show a variegate spectrum of both thrombotic and
haemorrhagic complications. Among angiogenesis
inhibitors, treatment with sorafenib is poorly com-
plicated with thrombotic episodes. Conversely,
bleeding has been extensively reported with an
incidence of 2–3% of treated patients, ranging from
frequent and mild [2] to rare severe haemorrhages,
including intracranial [3].
Hepatocellular carcinoma frequently occurred in
haemophiliacs as most patients became infected with
HBV and HCV from concentrates before virus
inactivation was available. Since infected concen-
trates were used in the early-mid 1980s, HCC
emerged as a cause of death in haemophiliacs
beginning from the mid 1990s [4]. Liver transplan-
tation and chemoembolization are the therapeutic
options [5] while the use of sorafenib for HCC
treatment has never been reported in haemophiliacs
to date.
A 65 year-old severe haemophiliac A with chronic
HBV/HCV-related liver co-infection referred to our
Centre for a markedly increased serum alpha-
fetoprotein (AFP) (4102 ng/mL). A liver ultrasound
was performed, showing a nodular lesion (diameter
5 cm) between the 6th and 7th segments. A further
superficial, extruding lesion (diameter 3 cm, 6th
segment) was detected at MRI. Hilar lymphadenop-
athy was present. Clinical diagnosis of multifocal
HCC was therefore made according to American
Association for the Study of Liver Diseases (AASLD)
diagnostic criteria (lesion >2 cm in cirrhotic liver, the
typical pattern of vascularization, confirmed by two
imaging studies, AFP >200 ng/mL). The patient was
asymptomatic at the time of observation. The func-
tional liver status, according to Child-Pugh score was
CHILD A (6 points). The patient fell in the stage B,
intermediate, thus surgically unresectable, according
to the Barcelona Clinic Liver Cancer Criteria (BCLC)
and chemoembolization of the nodular lesion
between the 6th and 7th segments with doxorubicin
(30 mg total dose) and Lipiodol was performed. As
the patients treatment regimen was on-demand
basis, adequate peri-operative coverage with his
plasma-derived factor VIII (FVIII) concentrate (Emo-
clot; Kedrion, Castelvecchio Pascoli, Italy) was
obtained. The subsequent CT scan, performed
4 weeks after the procedure, showed progression in
size of the main lesion (Fig. 1a), expansion of hilar
lymphadenopathy and the occurrence of new smaller
hepatic lesions, with worsening of performance
status (PS 2), thus determining a stage C, according
to BCLC criteria. At this point, the only residual
treatment option was a systemic therapy with the
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angiogenesis inhibitor sorafenib. Several co-morbid-
ities were present, including hypertension and hyper-
trophic cardiomyopathy, type II diabetes, and
especially haemorrhagic diathesis resulting from
haemophilia A, in that the patient was characterized
as unstable according to the Cumulative Illness
Rating Scale (CIRS) co-morbidity index score.
Therefore, treatment with sorafenib was started at
the 50% dose reduction of 400 mg/day. In order to
prevent bleeding episodes, the regimen of
substitution treatment with his plasma-derived FVIII
concentrate was shifted to prophylaxis (40 U/Kg
of body weight three times a week) as such regimen
is associated with a better long-term outcome
when compared with on-demand treatment. After
4 weeks of treatment, the patient only experienced
transient diarrhoea, and both moderate asthenia and
dyspnoea, while no bleeding episode was reported.
Furthermore, a consistent reduction of AFP (26.5 ng/
mL) was observed. Treatment was continued at the
same dose for further 4 weeks. Then a complete
restaging was performed. CT scan showed a good
response consisting in 50% reduction with extensive
central necrosis of the larger lesion (Fig. 1b), stability
of the superficial lesion, and disappearance of the
other satellite smaller nodules. AFP further decreased
down to 8 ng/mL and no bleeding symptom was
reported. Three months after discontinuing sorafenib
treatment, our patient preserved his basic perfor-
mance status and AFP still fell into the normal range
(8.9 ng/mL). Prophylaxis with FVIII has not been
discontinued.
This is, to date, the first report of the use of
sorafenib for treatment of HCC in a haemophiliac.
Our experience suggests that Sorafenib may be a
feasible therapeutic option in these patients. As a
result of the bleeding complications described with
the use of this drug, prophylaxis with FVIII concen-
trates is advised. The reasons for such an effective
response when compared with the case of non-
haemophiliac patients after an 8-week course ther-
apy administered at half the full dose require further
studies and sorafenib needs a large scale comparison
with other treatment options in hemophiliac patients
affected by HCC.
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Fig. 1. (a) CT scan performed 4 weeks after chemoembolization shows progression in size of the nodular lesion between the 6th and 7th
segments with persistence of viable tissue (arrow). (b) CT scan performed after 8-week course treatment with sorafenib shows marked
reduction in size of the nodular lesion between the 6th and 7th segments with intra-lesional necrosis (arrow).
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